{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:37:51Z","timestamp":1774957071651,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T00:00:00Z","timestamp":1480118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>As part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T) we report the in vitro activity of tigecycline and its comparators against Gram-negative and Gram-positive organisms collected from Italian centers between 2012 and 2014. Minimum inhibitory concentrations were determined according to the broth microdilution methodology of the Clinical and Laboratory Standards Institute, and antimicrobial resistance was determined using the European Committee on Antimicrobial Susceptibility Testing interpretive criteria. Among the Enterobacteriaceae, 31% of Escherichia coli isolates, 22% of Klebsiella pneumoniae, and 1% of Klebsiella oxytoca were extended-spectrum \u03b2-lactamase producers (ESBLs). Resistance rates among ESBL-K. pneumoniae and ESBL-E. coli to meropenem were 24% and &lt;1%, respectively. Thirty-seven percent of K. pneumoniae were multidrug resistant (MDR) strains. Resistance rates among isolates of Acinetobacter baumannii to amikacin, levofloxacin and meropenem were between 84% and 94%. Eighty percent of A. baumannii isolates were MDR strains. Methicillin-resistant Staphylococcus aureus (MRSA) accounted for 38% of S. aureus isolates. No isolates of MRSA were resistant to linezolid, tigecycline or vancomycin. Antimicrobial resistance remains a problem in Italy with increasing numbers of MDR organisms. Despite high levels, MRSA rates appear to be stabilising. Tigecycline retains its in vitro activity against the majority of organisms, including those with multidrug resistance.<\/jats:p>","DOI":"10.3390\/ph9040074","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T10:25:22Z","timestamp":1480328722000},"page":"74","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-7427","authenticated-orcid":false,"given":"Stefania","family":"Stefani","sequence":"first","affiliation":[{"name":"Department of Bio-Medical Sciences, University of Catania, Via Androne 81, Catania 95124, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dowzicky","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,11,26]]},"reference":[{"key":"ref_1","unstructured":"European Center for Disease Prevention and Control (2015). Antimicrobial Resistance Surveillance in Europe 2014; Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), ECDC."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijmm.2010.04.003","article-title":"Antibiotic use: How to improve it?","volume":"300","author":"Hulscher","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3716","article-title":"General population\u2019s knowledge and attitudes about antibiotics: A systematic review and meta-analysis","volume":"24","author":"Gualano","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jgar.2015.06.006","article-title":"Epidemiology of Staphylococcus aureus in Italy: First nationwide survey, 2012","volume":"3","author":"Campanile","year":"2015","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.18.22.20489-en","article-title":"Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: Results of the first countrywide survey, 15 May to 30 June 2011","volume":"18","author":"Giani","year":"2013","journal-title":"Euro Surveill."},{"key":"ref_6","unstructured":"Pfizer Inc. (Wyeth Pharmaceuticals) (2013). Tygacil\u00ae Package Insert, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021821s026s031lbl.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/ph6111381","article-title":"Longitudinal assessment of antimicrobial susceptibility among Gram-negative and Gram-positive organisms collected from Italy as part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011","volume":"6","author":"Stefani","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_8","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2016). Breakpoint Tables for Interpretation of MICs and Zone Diameters, European Society of Clinical Microbiology and Infectious Disease. Available online: http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhin.2010.08.009","article-title":"Progress in infection prevention and control in Italy: A nationwide survey","volume":"77","author":"Moro","year":"2011","journal-title":"J. Hosp. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Charrier, L., Argentero, P.A., Farina, E.C., Serra, R., Mana, F., and Zotti, C.M. (2014). Surveillance of healthcare-associated infections in Piemonte, Italy: Results from a second regional prevalence study. BMC Public Health, 14.","DOI":"10.1186\/1471-2458-14-558"},{"key":"ref_11","unstructured":"Clinical Laboratory Standards Institute (CLSI) (2013). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [20th ed.]. CLSI Supplement M100-S23."},{"key":"ref_12","unstructured":"Clinical Laboratory Standards Institute (CLSI) (2008). Development of in Vitro Susceptibility Testing Criteria and Quality Control Parameters, Approved Guideline, CLSI. [3rd ed.]. CLSI Document M23-A3."},{"key":"ref_13","unstructured":"European Committee on Antimicrobial Susceptibility Testing Setting Breakpoints for New Antimicrobial Agents, EUCAST SOP 1.1, 2013. Available online: http:\/\/www.eucast.org\/documents\/sops\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2334-12-181","article-title":"Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?","volume":"12","author":"Marchese","year":"2012","journal-title":"BMC Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jac\/dkr524","article-title":"Effects of clinical breakpoint changes in CLSI guidelines 2010\/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting Gram-negative bacilli","volume":"67","author":"Hombach","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1111\/1469-0691.12090","article-title":"The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidleines","volume":"19","author":"Hombach","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.diagmicrobio.2013.10.008","article-title":"Resistance surveillance program report for selected European nations (2011)","volume":"78","author":"Jones","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","article-title":"Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe","volume":"18","author":"Carmeli","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2047-2994-2-6","article-title":"The rise in carbapenem resistance in Europe: Just the tip of the iceberg?","volume":"2","author":"Magiorakos","year":"2013","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill."},{"key":"ref_21","unstructured":"European Center for Disease Prevention and Control (2013). Carbapenemase-Producing Bacteria in Europe: Interim Results from the European Survey on Carbapenemases-Producing Enterobacteriaceae (EuSCAPE) Project, ECDC."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jinf.2015.10.008","article-title":"Comprehensive clinical and epidemiological assessment of colonization and infection due to carbapenemase-producing Enterobacteriaceae in Spain","volume":"72","author":"Oteo","year":"2016","journal-title":"J. Infect."},{"key":"ref_23","unstructured":"European Center for Disease Prevention and Control (2014). Antimicrobial Resistance Surveillance in Europe 2013, ECDC. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-0711-7-4","article-title":"In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy","volume":"7","author":"Mezzatesta","year":"2008","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2013.02.022","article-title":"Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004\u20132010","volume":"41","author":"Balode","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jgar.2016.02.005","article-title":"Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T. E.S.T.) in Spain, 2004\u20132014","volume":"6","author":"Marco","year":"2016","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diagmicrobio.2009.03.001","article-title":"ZAPPS International Surveillance Program (2007) for linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries","volume":"64","author":"Jones","year":"2009","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"Morales","year":"2010","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1179\/joc.2011.23.2.71","article-title":"Eight-year (2002\u20132009) summary of the linezolid (Zyvox\u00ae Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries","volume":"23","author":"Ross","year":"2011","journal-title":"J. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02187-13","article-title":"Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States","volume":"52","author":"Limbago","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(13)61219-2","article-title":"First case of infection with vancomycin-resistant Staphylococcus aureus in Europe","volume":"382","author":"Resina","year":"2013","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a University Hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant (MRSA) blood isolates from 2001 to 2005","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1128\/AAC.00616-09","article-title":"Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_38","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2015). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, CLSI. [Approved Standard 10th ed.]. Document MO7-A10."},{"key":"ref_39","unstructured":"Clinical Laboratory Standards Institute (CLSI) (2016). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [26th ed.]. CLSI Supplement M100S."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/9\/4\/74\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:30Z","timestamp":1760210850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/9\/4\/74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,26]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["ph9040074"],"URL":"https:\/\/doi.org\/10.3390\/ph9040074","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,26]]}}}